Your Health, We Care
On March 22, 2024, the U.S. FDA approved expanded broad indication labeling for Nexletol and Nexlizet for the prevention of heart attacks and cardiovascular interventions in patients for primary and secondary prevention, regardless of statin use.
On December 13, 2023, the U.S. FDA updated the low-density lipoprotein cholesterol (LDL‑C) lowering indications for Esperion Therapeutics' Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid/ezetimibe) tablets.
On February 21, 2020, the FDA approved Nexletol (bempedoic acid) for the reduction of low-density lipoprotein cholesterol.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
